Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery

Background: Systemic treatment options for metastatic renal cell carcinoma (RCC) have significantly expanded in recent years. However, patients refractory to tyrosine kinase and immune checkpoint inhibitors still have limited treatment options and patient-individualized approaches are largely missin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jielin, Pohl, Laura, Schüler, Julia, Korzeniewski, Nina, Reimold, Philipp, Kaczorowski, Adam, Hou, Weibin, Zschäbitz, Stefanie, Nientiedt, Cathleen, Jäger, Dirk, Hohenfellner, Markus, Duensing, Anette, Duensing, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227814/
https://www.ncbi.nlm.nih.gov/pubmed/34072926
http://dx.doi.org/10.3390/biomedicines9060627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227814/
https://www.ncbi.nlm.nih.gov/pubmed/34072926
http://dx.doi.org/10.3390/biomedicines9060627

Ejemplares similares